Among the 169 NSCLC patients with EGFR active mutations, 3 (1.8%) achieved CR, and 65 (38.5%) had PR, 87 (51.5%) had SD, and 14 (8.3%) had PD. This evidence concerns the gene EGFR and non-small cell lung carcinoma.